Treatments of refractory eosinophilic lung diseases with biologics

  • Asano Koichiro
    Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine
  • Suzuki Yuzo
    Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
  • Tanaka Jun
    Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine
  • Kobayashi Konomi
    Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine
  • Kamide Yosuke
    Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital

抄録

<p>Biologics targeting the molecules associated with type 2 inflammation have significantly improved the outcomes of patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Chronic eosinophilic airway/lung diseases including chronic eosinophilic pneumonia, allergic bronchopulmonary aspergillosis/mycosis, eosinophilic bronchitis, and eosinophilic granulomatosis with polyangiitis share clinical features with eosinophilic asthma and CRPwNP, which are mostly adult-onset and may develop simultaneously or consecutively. These eosinophilic airway/lung diseases respond well to initial treatment with systemic corticosteroids, but often recur when the corticosteroids are tapered. The management of these “refractory” cases is an unmet need for clinicians. We first reviewed the standard treatments for these chronic eosinophilic airway/lung diseases, followed by the definition and prevalence of refractory diseases and the role of biologics in their management. The available evidence varies from case reports and case series to randomized control trials, depending on the type of disease; however, these studies provide not only a direction for clinical practice, but also insights into the pathophysiology of each disease. Physicians should discuss the efficacy and costs of biologics in patients with refractory eosinophilic airway/lung diseases to minimize not only the current symptoms, but future risks as well.</p>

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (114)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ